Talvey(talquetamab)
Talvey (talquetamab) is an antibody pharmaceutical. Talquetamab was first approved as Talvey on 2023-08-09. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target G-protein coupled receptor family C group 5 member D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Talvey
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Talquetamab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Talvey | talquetamab-tgvs | Johnson & Johnson | N-761342 RX | 2023-08-09 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| talvey | Biologic Licensing Application | 2025-10-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
talquetamab, Talvey, Janssen Biotech, Inc. | |||
| 2030-08-09 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 9 | 19 | 4 | — | 4 | 34 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 8 | 1 | — | 2 | 13 |
| Recurrence | D012008 | — | — | 1 | 1 | 1 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 2 |
| Residual neoplasm | D018365 | — | — | — | 2 | — | — | — | 2 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | 1 | — | — | — | 1 |
| Smoldering multiple myeloma | D000075122 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | — | — | 1 | 1 |
| Plasma cell leukemia | D007952 | — | C90.1 | — | — | — | — | 1 | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Talquetamab |
| INN | talquetamab |
| Description | Talquetamab, sold under the brand name Talvey, is a humanized monoclonal antibody used for the treatment of multiple myeloma. It is a bispecific GPRC5D-directed CD3 T-cell engager. Talquetamab is a bispecific antibody against two targets: human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen with potential antineoplastic activity. Talquetamab binds both targets, drawing the T cells close to the tumor cells, causing a cytotoxic T-lymphocyte response. It is being developed by Janssen Pharmaceuticals.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2226212-40-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594503 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16678 |
| UNII ID | 4W3KFI3TN3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Talvey – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 657 documents
View more details
Safety
Black-box Warning
Black-box warning for: Talvey
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,255 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use